Biologics are now important components of targeted therapy for malignancy. But so far, clinical trials using biologics in the treatment of non small cell lung cancer (NSCLC) have been disappointing. Results have shown inconsistent benefits and failure of biologics to prolong patient survival, when in combination with chemotherapy. However, if platinum-based therapy fails, the question […]
written on 30.04.2014
Biologics in Non Small Cell Lung Cancer (NSCLC) – Part I: Current Status, 2014
